All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

10

Reset

10 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • VC005Phase 35 trials

    Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis

  • RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials

    Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata

  • SYHX1901Phase 32 trials

    CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata

  • CTP-543Phase 31 trial

    Sun Pharmaceutical Industries, Inc. · Alopecia Areata

  • IMG-007Phase 23 trials

    Inmagene LLC · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema

  • ADX-914bempikibartPhase 22 trials

    Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata

  • LY4005130Phase 22 trials

    Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)

  • ALD-102Phase 21 trial

    Aldena Therapeutics · Alopecia Areata (AA)

  • LAD603Phase 21 trial

    Almirall, S.A. · Alopecia Areata

  • NXC736Phase 21 trial

    NEXTGEN Bioscience · Alopecia Areata

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.